• Verastem dosed the first patient in TARGET-D 201, a Phase 2 registration-directed study of oral KRAS G12D inhibitor VS-7375 in metastatic pancreatic cancer.
• No trial results were presented; the update marks study start-up, with future data expected as enrollment and follow-up progress.
• The trial tests VS-7375 alone or with cetuximab in second-line disease, with a cohort evaluating the combination as a potential chemotherapy-free frontline option.
• The program targets a common pancreatic cancer mutation linked to poor outcomes, positioning VS-7375 as a potential new targeted option in an area with no approved KRAS G12D drugs.
• VS-7375 previously received FDA Fast Track designation in pancreatic cancer, supporting an accelerated development and regulatory path if clinical activity holds up.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606161601BIZWIRE_USPR_____20260616_BW690184) on June 16, 2026, and is solely responsible for the information contained therein.